# Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections

> **NCT03840616** · PHASE3 · COMPLETED · sponsor: **Mycovia Pharmaceuticals Inc.** · enrollment: 219 (actual)

## Conditions studied

- Recurrent Vulvovaginal Candidiasis

## Interventions

- **DRUG:** Oteseconazole (VT-1161) 150mg capsule
- **DRUG:** Fluconazole 150mg capsule
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03840616
- **Lead sponsor:** Mycovia Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-13
- **Primary completion:** 2020-12-02
- **Final completion:** 2020-12-02
- **Target enrollment:** 219 (ACTUAL)
- **Last updated:** 2022-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03840616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03840616, "Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03840616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*